We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cardiovascular Systems Inc | NASDAQ:CSII | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.00 | 19.99 | 20.00 | 0 | 01:00:00 |
From Jun 2022 to Jun 2024
By Kathryn Hardison
Abbott Laboratories plans to acquire medical-device company Cardiovascular Systems Inc. in a deal that will boost Abbott's vascular disease offerings.
Under the terms, Cardiovascular Systems stockholders will receive $20 per common share at a total expected equity value of about $890 million, the companies said Wednesday.
Cardiovascular Systems, or CSI, specializes in devices for atherectomy, a minimally invasive treatment for plaque build-up in arteries that can restrict blood flow, the companies said. It also has an early-stage pipeline of complementary vascular intervention devices in development.
The transaction, which has been approved by the boards of directors of CSI and Abbott, is subject to the approval of CSI stockholders and applicable regulatory approvals.
J.P. Morgan Securities LLC is serving as financial adviser to CSI.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
February 08, 2023 18:37 ET (23:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Cardiovascular Systems Chart |
1 Month Cardiovascular Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
